Progress in early diagnosis and management of sleep disorder in patients with Alzheimer's disease

doi:10.3969/j.issn.1672-6731.2021.12.004

Abstract

Abstract: Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive dysfunction and mental behavioral impairment. Sleep disorder is not only a common clinical symptom of AD, but also a risk factor for accelerating the pathological progression of the disease and cognitive impairment. As there is no effective intervention target for AD at present, sleep disorder is a controllable risk factor for AD, and early and correct diagnosis and management of sleep disorder play a key role in delaying the progression of AD. This article reviews the clinical manifestations, risk factors, early screening and management of sleep disorder in AD, in order to explore new therapeutic targets for AD from the perspective of sleep.

Key words: Alzheimer disease, Sleep disorders, Amyloid beta-peptides, Tau proteins, Review

摘要： 阿尔茨海默病是以进行性认知功能障碍和精神行为异常为特征的神经变性病。睡眠障碍既是阿尔茨海默病的常见临床症状，又是加速疾病进展和认知功能障碍的危险因素，二者存在交互作用。由于目前阿尔茨海默病尚无有效干预靶点，睡眠障碍作为其可控危险因素，早期准确诊断并管理睡眠障碍对延缓阿尔茨海默病进展具有重要作用。本文综述阿尔茨海默病睡眠障碍的临床表现、危险因素、早期筛查及管理，以期从睡眠角度探索阿尔茨海默病治疗的新靶点。

关键词: 阿尔茨海默病, 睡眠障碍, 淀粉样β肽类, tau蛋白质类, 综述

TANG Shi, DU Yi-feng. Progress in early diagnosis and management of sleep disorder in patients with Alzheimer's disease[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(12): 1042-1045.

唐诗, 杜怡峰. 阿尔茨海默病患者睡眠障碍早期诊断与管理进展[J]. 中国现代神经疾病杂志, 2021, 21(12): 1042-1045.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2021.12.004

https://journal11.magtechjournal.com/cjcnn/EN/Y2021/V21/I12/1042

References

[1] Writing Group of Guidelines for Diagnosis and Treatment of Dementia and Cognitive Impairment in China, Cognitive Disorders Professional Committee of the Neurologist Branch of the Chinese Medical Doctor Association. Chinese guidelines for the primary prevention of Alzheimer's disease[J]. Zhonghua Yi Xue Za Zhi, 2020, 100:2721-2735.[中国痴呆与认知障碍诊治指南写作组,中国医师协会神经内科医师分会认知障碍疾病专业委员会.中国阿尔茨海默病一级预防指南[J].中华医学杂志, 2020, 100:2721-2735.]
[2] Wang P, Song L, Wang K, Han X, Cong L, Wang Y, Zhang L, Yan Z, Tang S, Du Y. Prevalence and associated factors of poor sleep quality among Chinese older adults living in a rural area:a population-based study[J]. Aging Clin Exp Res, 2020, 32:125-131.
[3] Guarnieri B, Adorni F, Musicco M, Appollonio I, Bonanni E, Caffarra P, Caltagirone C, Cerroni G, Concari L, Cosentino FI, Ferrara S, Fermi S, Ferri R, Gelosa G, Lombardi G, Mazzei D, Mearelli S, Morrone E, Murri L, Nobili FM, Passero S, Perri R, Rocchi R, Sucapane P, Tognoni G, Zabberoni S, Sorbi S. Prevalence of sleep disturbances in mild cognitive impairment and dementing disorders:a multicenter Italian clinical cross-sectional study on 431 patients[J]. Dement Geriatr Cogn Disord, 2012, 33:50-58.
[4] Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer's disease:role of amyloid, tau, and other factors[J]. Neuropsychopharmacology, 2020, 45:104-120.
[5] Harris SS, Schwerd-Kleine T, Lee BI, Busche MA. The Reciprocal interaction between sleep and Alzheimer's disease[J]. Adv Exp Med Biol, 2021, 1344:169-188.
[6] Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia[J]. Science, 2020, 370:50-56.
[7] Cordone S, De Gennaro L. Insights from human sleep research on neural mechanisms of Alzheimer's disease[J]. Neural Regen Res, 2020, 15:1251-1252.
[8] Holth J, Patel T, Holtzman DM. Sleep in Alzheimer's disease:beyond amyloid[J]. Neurobiol Sleep Circadian Rhythms, 2017, 2:4-14.
[9] Kuang H, Zhu YG, Zhou ZF, Yang MW, Hong FF, Yang SL. Sleep disorders in Alzheimer's disease:the predictive roles and potential mechanisms[J]. Neural Regen Res, 2021, 16:1965-1972.
[10] Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Association between circadian rhythms and neurodegenerative diseases[J]. Lancet Neurol, 2019, 18:307-318.
[11] Canevelli M, Valletta M, Trebbastoni A, Sarli G, D'Antonio F, Tariciotti L, de Lena C, Bruno G. Sundowning in dementia:clinical relevance, pathophysiological determinants, and therapeutic approaches[J]. Front Med (Lausanne), 2016, 3:73.
[12] Liguori C, Maestri M, Spanetta M, Placidi F, Bonanni E, Mercuri NB, Guarnieri B. Sleep-disordered breathing and the risk of Alzheimer's disease[J]. Sleep Med Rev, 2021, 55:101375.
[13] Bubu OM, Umasabor-Bubu OQ, Turner AD, Parekh A, Mullins AE, Kam K, Birckbichler MK, Mukhtar F, Mbah AK, Williams NJ, Rapoport DM, de Leon M, Jean-Louis G, Ayappa I, Varga AW, Osorio RS; Alzheimer's Disease Neuroimaging Initiative. Self-reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time-dependent progression[J]. Alzheimers Dement, 2020, 8:10.
[14] Sleep Disorder Group of Neurology Branch of Chinese Medical Association. Guidelines for diagnosis and treatment of insomnia in Chinese adults[J]. Zhonghua Shen Jing Ke Za Zhi, 2012, 45:534-540.[中华医学会神经病学分会睡眠障碍学组.中国成人失眠诊断与治疗指南[J].中华神经科杂志, 2012, 45:534-540.]
[15] Blackman J, Swirski M, Clynes J, Harding S, Leng Y, Coulthard E. Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease:a systematic review[J]. J Sleep Res, 2021, 30:e13229.
[16] Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, Frydman-Marom A, Zisapel N. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease:a 6-month, randomized, placebo-controlled, multicenter trial[J]. Clin Interv Aging, 2014, 9:947-961.
[17] Moraes Wdos S, Poyares DR, Guilleminault C, Ramos LR, Bertolucci PH, Tufik S. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease:a double-blind placebo-controlled study[J]. Sleep, 2006, 29:199-205.
[18] McCleery J, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia[J]. Cochrane Database Syst Rev, 2020, 11:CD009178.
[19] Knutson KL, Rathouz PJ, Yan LL, Liu K, Lauderdale DS. Stability of the pittsburgh sleep quality index and the epworth sleepiness questionnaires over 1 year in early middle-aged adults:the CARDIA study[J]. Sleep, 2006, 29:1503-1506.
[20] Johns MW. A new method for measuring daytime sleepiness:the Epworth sleepiness scale[J]. Sleep, 1991, 14:540-545.
[21] Senaratna CV, Perret JL, Matheson MC, Lodge CJ, Lowe AJ, Cassim R, Russell MA, Burgess JA, Hamilton GS, Dharmage SC. Validity of the Berlin questionnaire in detecting obstructive sleep apnea:a systematic review and meta-analysis[J]. Sleep Med Rev, 2017, 36:116-124.
[22] Mecacci L, Zani A. Morningness-eveningness preferences and sleep-waking dairy data of morning and evening types in student and worker samples[J]. Ergonomics, 1983, 26:1147-1153.
[23] Cipriani G, Lucetti C, Danti S, Nuti A. Sleep disturbances and dementia[J]. Psychogeriatrics, 2015, 15:65-74.
[24] Camargos EF, Louzada FM, Nóbrega OT. Wrist actigraphy for measuring sleep in intervention studies with Alzheimer's disease patients:application, usefulness, and challenges[J]. Sleep Med Rev, 2013, 17:475-488.
[25] Kent BA, Feldman HH, Nygaard HB. Sleep and its regulation:an emerging pathogenic and treatment frontier in Alzheimer's disease[J]. Prog Neurobiol, 2021, 197:101902.
[26] Zhou X, Wang Y, Lv S, Li Y, Jia S, Niu X, Peng D. Transcranial magnetic stimulation for sleep disorders in Alzheimer's disease:a double-blind, randomized, and sham-controlled pilot study[J]. Neurosci Lett, 2022, 766:136337.
[27] Burke SL, Hu T, Spadola CE, Burgess A, Li T, Cadet T. Treatment of sleep disturbance may reduce the risk of future probable Alzheimer's disease[J]. J Aging Health, 2019, 31:322-342.
[28] Yin Y, Liu Y, Zhuang J, Pan X, Li P, Yang Y, Li YP, Zhao ZQ, Huang LQ, Zhao ZX. Low-dose atypical antipsychotic risperidone improves the 5-year outcome in Alzheimer's disease patients with sleep disturbances[J]. Pharmacology, 2015, 96:155-162.
[29] Vecchierini MF, Kilic-Huck U, Quera-Salva MA; Members of the MEL consensus group of the SFRMS. Melatonin (MEL) and its use in neurological diseases and insomnia:recommendations of the French Medical and Research Sleep Society (SFRMS)[J]. Rev Neurol (Paris), 2021, 177:245-259.
[30] Dauvilliers Y. Insomnia in patients with neurodegenerative conditions[J]. Sleep Med, 2007, 8:S27-34.
[31] Ju YS, Zangrilli MA, Finn MB, Fagan AM, Holtzman DM. Obstructive sleep apnea treatment, slow wave activity, and amyloid-β[J]. Ann Neurol, 2019, 85:291-295.
[32] Kuo CY, Hsiao HT, Lo IH, Nikolai T. Association between obstructive sleep apnea, its treatment, and Alzheimer's disease:systematic mini-review[J]. Front Aging Neurosci, 2021, 12:591737.

Please choose a citation manager

Content to export